BSX
NYSE · Health Care
Boston Scientific Corp
$76.27
-1.37 (-1.76%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 16.71B | 14.91B | 99.35B | 92.67B | 78.46B |
| Net Income | 1.85B | 1.49B | 6.84B | 6.21B | 4.86B |
| EPS | — | — | — | — | — |
| Profit Margin | 11.1% | 10.5% | 6.9% | 6.7% | 6.2% |
| Rev Growth | +12.1% | +12.1% | +1.5% | +24.5% | -0.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 18.69B | 18.69B | 47.75B | 41.85B | 48.83B |
| Total Equity | 37.86B | 37.86B | 39.96B | 39.78B | 34.13B |
| D/E Ratio | 0.49 | 0.49 | 1.19 | 1.05 | 1.43 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 3.42B | 2.90B | 12.97B | 11.32B | 10.30B |
| Free Cash Flow | — | — | 5.36B | 4.47B | 5.22B |